Shilpa Medicare Limited , a prominent Indian pharmaceutical company, has successfully completed a significant corporate action through a postal ballot process. The company announced that its shareholders have approved the reclassification of two promoter group members to the public category.

Key Details of the Reclassification

The postal ballot, which ran from October 9 to November 8, 2025, sought shareholder approval for two ordinary resolutions:

1. Reclassification of Mr. Suraj Kumar Inani from the "Promoter group" category to the "Public" category
2. Reclassification of Ms. Priya Inani from the "Promoter group" category to the "Public" category

Both resolutions passed with an overwhelming majority, receiving over 97% votes in favor.

Voting Process and Timeline

The scrutinizer confirmed that the voting process was conducted fairly and transparently, in accordance with regulatory requirements.

Implications and Compliance

This reclassification aligns with the regulatory framework set by the Securities and Exchange Board of India (SEBI) for the reclassification of promoter group members. It reflects Shilpa Medicare's commitment to maintaining transparency in its shareholding structure and adhering to corporate governance best practices.

The company has duly informed the stock exchanges - BSE Limited and the National Stock Exchange of India Limited - about the results of the postal ballot, in compliance with Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

As Shilpa Medicare continues to focus on its core pharmaceutical business, including the development of APIs, formulations, and biologics across various therapeutic segments, this corporate action demonstrates the company's proactive approach to shareholder engagement and regulatory compliance.

Investors and market watchers may view this development as part of Shilpa Medicare's ongoing efforts to streamline its ownership structure, potentially impacting the company's governance dynamics going forward.

Shilpa Medicare , a leading pharmaceutical company, has announced two significant developments: its subsidiary's sustainability achievement and positive clinical trial results for a new drug.

EcoVadis Gold Medal for Sustainability Excellence

Shilpa Medicare's material subsidiary, Shilpa Pharma Life Sciences Limited, has been awarded the prestigious Gold Medal by EcoVadis, the world's most trusted provider of business sustainability ratings, for its excellence in sustainability practices.

Outstanding Performance in Sustainability

Shilpa Pharma Life Sciences demonstrated exceptional performance in EcoVadis' comprehensive assessment, scoring an impressive 82 out of 100. This remarkable score places the company in the 98th percentile globally among over 130,000 companies evaluated by EcoVadis.

Key Assessment Areas

EcoVadis' evaluation focused on four crucial pillars of sustainability:

Strategic Implications

Mr. Keshav Bhutada, ED & CEO of Shilpa Pharma Life Sciences, emphasized the strategic importance of this recognition, stating, "Sustainability and innovation are integral to Shilpa's CDMO growth strategy to work with global innovator companies for their New Chemical Entity programs."

The EcoVadis Gold Medal significantly enhances Shilpa's credentials in the global pharmaceutical landscape:

1. Trusted CDMO Partner: Strengthens Shilpa's position as a reliable Contract Development and Manufacturing Organization (CDMO) partner for global innovator companies.
2. Investor Confidence: Boosts investor confidence by demonstrating the company's commitment to sustainable and ethical business practices.
3. Competitive Edge: Provides a competitive advantage in the pharmaceutical industry, where sustainability is becoming increasingly important.

Positive Phase 3 Results for Oeris™ Drug

In a separate development, Shilpa Medicare has announced positive Phase 3 clinical trial results for its drug Oeris™. The treatment showed promising outcomes:

• 89% complete response rate for Oeris™
• 82% complete response rate for standard treatment
• No serious side effects observed during the trial

Based on these encouraging results, Shilpa Medicare plans to submit Oeris™ for regulatory approval.

Long-term Commitment to Sustainability and Innovation

These achievements underscore Shilpa Medicare's long-term commitment to building a responsible, resilient, and sustainable pharmaceutical enterprise. The company's focus on sustainability, innovation, and drug development positions it well for future growth and partnerships with global innovator companies.

As the pharmaceutical industry continues to evolve, Shilpa Medicare's dual success in sustainability and drug development not only celebrates the company's current achievements but also sets a high standard for its future endeavors in the realm of sustainable pharmaceutical development, manufacturing, and innovation.